Filana Therapeutics (FLNA) EBITDA Margin (2010 - 2026)
Filana Therapeutics' EBITDA Margin came in at -74.55% for Q4 2012, down 54.57 percentage points from -19.99% a year earlier and down 15.73 percentage points from the prior quarter.
Powered by 
Analysis
Filana Therapeutics (FLNA) EBITDA Margin (2010 - 2026) Analysis & Trends
For FY2012, Filana Therapeutics' EBITDA Margin was -34.66%, down 5.49 percentage points from FY2011.
- EBITDA Margin carries a three-year change of -3.07 percentage points (FY2009 to FY2012).
- Going back by year, EBITDA Margin was -29.18% in FY2011 (+50.96 pp), -80.14% in FY2010 (-48.55 pp) and -31.60% in FY2009.
- The Q4 2012 figure represents the lowest quarterly EBITDA Margin since Q4 2010.
- Year-over-year, EBITDA Margin increased in four of the last six quarters, with an average year-over-year change of +14.80 percentage points.
- Business Quant data shows FLNA's EBITDA Margin at -58.83% (Q3 2012), -8.00% (Q2 2012) and -3.80% (Q1 2012) in the three quarters before Q4 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 39.16% |
| 10 | Filana Therapeutics | 32.11 Mn | -338.73 Mn | - | -1,217.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,217.27% |
| Mar 31, 2026 | -1,384.66% |
| Dec 31, 2025 | -1,360.27% |
| Sep 30, 2025 | -999.14% |
| Jun 30, 2025 | -3,722.57% |
| Mar 31, 2025 | -1,926.17% |
| Dec 31, 2024 | -1,633.50% |
| Sep 30, 2024 | -1,160.85% |
| Jun 30, 2024 | -2,635.84% |
| Mar 31, 2024 | -1,101.46% |
| Dec 31, 2023 | -1,420.71% |
| Sep 30, 2023 | -1,370.92% |
| Jun 30, 2023 | -1,291.45% |
| Mar 31, 2023 | -1,273.57% |
| Dec 31, 2022 | -1,322.27% |
| Sep 30, 2022 | -2,396.92% |
| Dec 31, 2012 | -74.55% |
| Sep 30, 2012 | -58.83% |
| Jun 30, 2012 | -8.00% |
| Mar 31, 2012 | -3.80% |
API Access
Filana Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=FLNA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "FLNA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=FLNA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();